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Abstract 
Background: Copeptin, part of the vasopressin precursor, is increasingly used as marker 
for vasopressin and is claimed to have better ex vivo stability. However, no study has 
directly compared the ex vivo stability of copeptin and vasopressin. 
Methods: Blood of ten healthy volunteers was collected in EDTA tubes. Next, we 
studied the effect of various pre-analytical conditions on measured vasopressin 
and copeptin levels: centrifugation speed, short-term storage temperature and 
differences between whole blood and plasma, long-term storage temperature 
and repeated freezing and thawing. The Acceptable Change Limit (ACL), 
indicating the maximal percentage change that can be explained by assay 
variability, was used as cut-off to determine changes in vasopressin and copeptin. 
Results: The ACL was 25% for vasopressin and 19% for copeptin. Higher centrifugation 
speed resulted in lower vasopressin levels, whereas copeptin concentration was 
unaffected. In whole blood, vasopressin was stable up to 2h at 25°C and 6h at 4°C. In plasma, 
vasopressin was stable up to 6h at 25°C and 24h at 4°C. In contrast, copeptin was stable in 
whole blood and plasma for at least 24h at both temperatures. At -20°C, vasopressin was 
stable up to 1 month and copeptin for at least four months. Both vasopressin and copeptin 
were stable after four months when stored at -80°C and -150°C. Vasopressin concentration 
decreased after 4 freeze-thaw cycles, whereas copeptin concentration was unaffected. 
Conclusion: Vasopressin levels were considerably affected by pre-analytical conditions, 
while copeptin levels were stable. Therefore, a strict sample handling protocol for 
measurement of vasopressin is recommended. 
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Introduction 
In clinical and epidemiological studies copeptin is increasingly used as marker for 
vasopressin, an important hormone for water homeostasis.1 Copeptin, a 39-aminoacid 
glycopeptide, is part of the vasopressin precursor hormone pre-pro-vasopressin. When 
this precursor is split, copeptin and vasopressin are produced in equimolar amounts.2 
It has been demonstrated that copeptin levels correlate well with vasopressin levels 
during physiological changes in plasma osmolality, from water excess to dehydration, 
and also in pathologic states, for example in septic shock.3-6 Moreover, a promising role 
for copeptin as a diagnostic marker in the differentiation of vasopressin-driven fluid 
homeostasis disorders as hyponatremia and polydipsia, and as prognostic marker in 
cardiovascular and kidney disease has emerged in literature.7-13
The rising popularity of copeptin as a surrogate marker for vasopressin is due to the 
laborious assay and presumed limited ex vivo stability of vasopressin in comparison 
with copeptin.2 However, a review of the literature reveals that the effects of various 
relevant pre-analytical conditions, such as centrifugation force and short- and long-
term storage conditions, on both vasopressin and especially copeptin have not been 
investigated (Table 1). The available evidence is sometimes contradictory and often out-
dated, since the method for vasopressin measurement has changed considerably over 
the past decades and results obtained in the past with the older assays may therefore 
not be valid.14 Moreover, no direct comparison of the ex vivo stability of vasopressin and 
copeptin has been made so far.
This study aimed to investigate the effect of centrifugation speed, various short-term 
storing conditions pre- and post-centrifugation, long-term freezer storage, and repeated 
freeze-thaw cycles on both copeptin and vasopressin levels in blood and plasma to 
provide evidence based instructions for optimal pre-analytical sample handling. 
Material and Methods
Study population and design 
Ten healthy volunteers were included in this study in December 2015. The study was 
performed in accordance with the principles of the Declaration of Helsinki and was 
exempted from review by the Medical Ethical Committee of the University Medical 
Center Groningen. All participants gave written informed consent. 
Blood sample collection was performed at 8:00 am after overnight fasting. Blood 
samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes and were 
immediately placed on ice for further sample distribution. Thereafter, several pre-
analytic sample handling procedures were evaluated. 
comparison of ex vivo stability of copeptin and vasopressin
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Table 1. Overview of literature on ex vivo stability of vasopressin and copeptin. 
Vasopressin Copeptin
Type of collection 
tube Plasma
In EDTA tubes more stable 
compared to serum tubes, 
no significant difference 
compared to heparin and 
fluoride tubes 27
In EDTA tubes more stable com-
pared to serum, heparin, and cit-
rate tubes after 14 days, however 
no difference initially 3,15
Centrifugation 
settings Plasma
Associated with platelet 
count and inversely asso-
ciated with centrifugation 
speed 14,22
Unknown
Storage at room 
temperature  
(up to 30°C)
Whole blood ↑ after 2 hours 14, 26 = up to 72 hours (although larger dispersion of data) 28
Plasma
↓ after 4 hours* 27; = up to 5 
hours 22; ≠ after 96 hours 16; ↓ 
after 12 hours* 17
= up to 14 days (although larger 
dispersion of data) 3
Storage at 4°C
Whole blood = up to 24h 
26; = up to 48 
hours 14 Unknown
Plasma = up to 5 hours 
16; ↓ after 2 
days* 16; = up to 5 days 21 = up to 14 days 
3
Freezer storage at 
-20°C Plasma ↓ after 24 hours** 
29 = up to 4 weeks 15
Freezer storage at 
-80°C Plasma = up to 1 month* 
17 Unknown
Freezer storage at 
-150°C Plasma Unknown Unknown
Freeze-thaw effect Plasma = 3 cycles 23; = 3 cycles* 17 = 4 cycles 3
Legend: =: stable; ↑: increase; ↓: decrease; ≠: change of more than 10%, decrease or increase not stated;  
*: measured synthetic vasopressin added to human plasma. All samples were collected in EDTA tubes except the 
study indicated by ** (heparin tubes).
To study the effect of relative centrifugal force (RCF), three EDTA tubes of every participant 
were centrifuged for 10 minutes at 4°C at 800 g, at 2000 g and at 5000 g, respectively. 
Immediately after centrifugation, platelet count, and plasma vasopressin and copeptin 
levels were determined. In all other experiments, plasma samples were obtained using 
an RCF of 2000 g for 10 minutes at 4°C, which is routine in clinical practice. Second, the 
effect of short-term storage duration and storage temperature before measurement of 
vasopressin and copeptin was studied. Whole blood and plasma samples were stored 
at 25°C and at 4°C for 2, 6 and 24 hours. Immediately after these storage periods, whole 
blood samples were centrifuged at 2000 g and together with the plasma samples stored 
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at -80°C until measurement of vasopressin and copeptin after 1 week. As reference, a 
plasma sample was stored at -80°C for 1 week immediately after collection. Third, the 
effect of long-term storage and freezer temperature on plasma levels of vasopressin 
and copeptin was evaluated. For each patient, samples were stored at three different 
temperatures (-20, -80, and -150°C). These samples were measured after 1 week, 1 month, 
and 4 months. Finally, the effect of one, two and four freeze-thaw cycles on the plasma 
concentration of vasopressin and copeptin was studied. During each cycle, a sample 
was frozen to -80°C and thereafter thawed to room temperature. Gradual temperature 
change, from -80°C to room temperature and vice versa, was ensured in all samples 
by storing samples first at -20°C for two hours before further processing. Samples that 
were stored at -150°C were transferred to -80°C for one night prior to thawing. 
Laboratory analysis
Vasopressin and copeptin measurements were performed in the clinical chemistry 
laboratory of the IJsselland Hospital, Capelle aan den IJssel, the Netherlands. 
Vasopressin was measured with a competitive radioimmunoassay using rabbit anti-
vasopressin-antiserum and a radio-iodinated vasopressin [125I] tracer (DRG Diagnostics, 
Marbug, Germany). Documented cross-reactivity of the used antibody with oxytocin is 
<0.1%. Solid phase extraction with acetic acid was performed to separate vasopressin 
from plasma with use of C18 columns (Waters Chromatography BV, Etten-Leur, The 
Netherlands). In our study, a recovery of 91.9 ± 2.5% was found. The detection limit of 
the vasopressin assay is 0.25 pmol/L. Values below the detection limit were considered 
equal to 0.25 pmol/L in the analyses.  
Copeptin was measured on a semi-automatic Kryptor analyser (ThermoFisher, 
Henningsdorf/Berlin, Germany) using a sandwich chemiluminescence immunoassay 
(ThermoFisher). Two antibodies, anti-copeptin sheep and anti-copeptin mouse 
antibodies with fluorescent proteins attached, are added to the blood samples and 
form a complex with copeptin. Upon activation with a nitrogen laser, the antibody-
copeptin complexes emits an elongated fluorescent signal compared to the free 
antibodies, allowing quantification of the copeptin concentration. The detection limit 
of the copeptin assay is 0.7 pmol/L. No values below this detection limit were found in 
this study.  
Assay functionality of vasopressin and copeptin was assessed by measuring high and 
low levels of the analytes in pooled plasma from human subjects in fourfold for five 
consecutive days according to the global Clinical and Laboratory Standards Institute 
(CLSI) EP15 protocol. In this way, the intra-assay and total coefficient of variation (CV) 
were determined. The intra-assay, or within-day CV was calculated by dividing the 
mean within-day standard deviation (SD within) by the grand mean of all measured 
values, times 100%. The total CV is derived from the SD of both within- and between day 
assay variation, which is calculated by using the formula: SD total = √ ((3/4) x SD within 
comparison of ex vivo stability of copeptin and vasopressin
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x SD within + B).18 B denotes the between-day variation, by averaging the differences 
between day means and the grand mean. The total SD was thereafter also divided by 
the grand mean, times 100%. 
Data analysis
All data is presented as median and interquartile range (IQR) because of our small 
sample size and skewed data distribution. For each participant separately, the 
percentage change in analyte concentration was calculated as Tsc/Tr×100 with Tr and 
Tsc representing the reference concentration and concentration of that study condition, 
respectively. These calculated changes were evaluated for presence of outliers, using 
Grubbs analysis.19,20 Outliers were excluded from analysis (Supplementary Table 1) and 
the mean percentage differences without outliers were compared with the Acceptable 
Change Limit (ACL). The ACL is the maximal percentage change that can be explained 
by assay variability, calculated with the following formula: ACL = Z √2 × CVa, with a 
Z-value of 1.96 thus representing a 95% confidence range.21 The analytical coefficient of 
variation (CVa) was obtained by dividing the SD of the data from the assay functionality 
assessment in the lower range of hormone concentration by the median concentration 
of the measured values at direct measurement. The ACL is considered our primary 
outcome analysis. Friedman’s ANOVA tests were performed as secondary analysis, with 
a post-hoc analysis of differences using Wilcoxon signed-rank tests, with Bonferroni 
corrections to correct for multiple testing. Correlations between vasopressin and 
copeptin concentrations were assessed using Spearman’s correlation analysis. P-values 
of <0.05 were considered statistically significant. All analyses were performed using 
SPSS (IBM Statistics version 22.0) and Graphpad Prism (version 5.0). 
Results 
Definition of change
The intra-assay CV of vasopressin was determined as 10.8% at 1.2 ± 0.1 pmol/L (low 
range) and 5.5% at 5.4 ± 0.3 pmol/L (high range). The total CV of vasopressin was 11% 
and 4.8% for the low and high range, respectively. The intra-assay CV of copeptin was 
9.0% at 3.0 ± 0.3 pmol/L (low range) and 2.2% at 28.9 ± 0.6 pmol/L (high range). The total 
CV of copeptin was 13.1% and 2.2% for the low and high range, respectively. The median 
vasopressin and copeptin values of samples centrifuged at 2000g were 1.46 pmol/L and 
5.73 pmol/L, respectively (Table 2). For the calculation of the ACL analytical CVs were 
estimated at 9.1% for vasopressin and 6.9% for copeptin. This resulted in an ACL of 25% 
for vasopressin and of 19% for copeptin. Change in hormone concentration during the 
various pre-analytical sample handling procedures was defined to be relevant in case 
this change exceeded these ACL values. 
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Effect of centrifugation speed 
As shown in Table 2, plasma platelet count gradually decreased when whole blood 
was centrifuged at higher relative centrifugal force (p<0.001). Plasma vasopressin 
concentration also decreased significantly at higher centrifugation speed, with 
respectively 73% and 86% when these whole blood samples were centrifuged at 2000 
g and 5000 g compared to 800 g, thus exceeding the ACL. In contrast, plasma copeptin 
levels did not differ across samples obtained with these three centrifugation speeds 
(Table 2). Plasma vasopressin and copeptin levels showed a significant correlation when 
blood samples were centrifuged at 2000 g and 5000 g (Spearmans’ r=0.84; p=0.002 and 
r=0.89; p<0.001, respectively) but not when blood samples were centrifuged at 800 g 
(Spearmans’ r=0.54; p=0.11). 
Effect of short-term storage
In whole blood stored at 25°C, an increase in vasopressin concentration of 48% was 
observed already after 2 hours of storage, and increased even further during longer 
storage at 25°C. In whole blood stored at 4°C, vasopressin was more stable, namely 
up to 6 hours (+20%). Copeptin concentrations in whole blood were stable at both 
temperatures for at least 24 hours (at 25°C +3% and at 4°C +1%). In plasma, vasopressin 
concentration remained stable up to 6 hours when stored at 25°C (+6%) and for at least 
24 hours when stored at 4°C (-2%). Again, copeptin concentration remained stable for 
all short-term storage conditions studied. These data are summarized in Table 3 and in 
Figure 1.
Table 2. Effect of relative centrifugation force (RCF) on platelet count and plasma vasopressin and 
copeptin levels.
800 g 2000 g 5000 g p-value





















[3.0 – 10.2] 0.74
Reference -3% -3%
Absolute values are provided as median and [interquartile range] in pmol/L. Percentages indicate mean 
percentage change compared to the reference value. A Exceeding the Acceptable Change Limit (predefined as 
25% for vasopressin and 19% for copeptin). S Statistically significant difference compared to reference value. 
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Table 3. Effect of short-term storage on plasma vasopressin and copeptin levels.











[1.7 – 8.4] <0.001
Reference +48%A +120%A +247%A






[1.0 – 3.6] 0.20










[2.8 – 10.7] 0.52
Reference ±0% ±0% +3%






[3.1 – 10.1] 0.97











[0.6 – 2.2] 0.05
Reference +10% +6% +34%A






[0.4 – 2.1] 0.60










[3.3 – 10.5] 0.77
Reference -1% +12% +11%






[3.4 – 9.9] 0.74
Reference +3% +7% +5%
Absolute values are provided as median and [interquartile range] in pmol/L. Percentages indicate mean percentage 
change compared to the reference value. A Exceeding the Acceptable Change Limit (predefined as 25% for 
vasopressin and 19% for copeptin). S p<0.05 compared to reference value.
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Figure 2. The effect of repeated freeze-thaw cycles on plasma vasopressin and copeptin concentration. 
Data points represent mean ± SD. The shaded areas represent the Acceptable Change Limits (ACL). 
Legend:  reference (100%). 
comparison of ex vivo stability of copeptin and vasopressin
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Figure 1. The effect of storage of whole blood and plasma at 4°C and 25°C on vasopressin and 
copeptin concentrations. Data points represent mean percentage change from baseline (reference). 
The horizontal dotted lines represent the Acceptable Change Limits (ACL). Legend: whole blood stored 
at 25°C;  whole blood stored at 4°C;  plasma stored at 25°C;  plasma stored at 4°C.
Effect of long-term storage
In Table 4, the effect of pre-measurement storage at -20°C, -80°C and -150°C for 1 week, 
1 month and 4 months is shown. Plasma levels measured immediately after blood 
withdrawal and centrifugation at 2000 g were used as reference. Plasma vasopressin 
levels decreased by 26% after 4 months in -20°C, exceeding the ACL of 25%. In contrast, 
vasopressin was stable for the total study duration in samples stored at -80°C and -150°C. 
Copeptin was stable during the entire study duration at all three storage temperatures.
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Effect of repeated freezing and thawing
Vasopressin was affected by repeated freezing and thawing as shown in Figure 2. After 
four cycles, vasopressin concentration exceeded the predefined ACL of 25% with a 
decrease of 32% from 1.5 [0.6 – 2.3] to 1.0 [0.3 – 1.3] pmol/L (p<0.001). However, even 
one freeze-thaw cycle already affected the vasopressin concentration although not 
exceeding the ACL with a decrease of 21% from 1.5 [0.6-2.3] to 1.2 [0.4 – 2.2] pmol/L 
(p<0.001). In contrast, copeptin concentration was not affected by repeated freezing 
and thawing  with a non siginifcant 2% decline after 4 cycles from 5.7 [2.9-10.5] to 5.6 
[3.1-10.7] pmol/L (p=0.08). Large individual differences in the effect of repeated freezing 
and thawing on plasma vasopressin levels were observed, with both positive as well as 
negative changes (Supplemental Figure 1).
Table 4. Long term storage.
Reference value 1 week 1 month 4 months P-value
Vasopressin






[0.3 – 2.0] 0.02
Reference -21% -9% -26%A






[0.6 – 2.6] 0.05
Reference -21% +11% -3%






[0.5 – 1.7] 0.93
Reference -5% +9% -2%
Copeptin






[3.3 – 10.4] 0.43
Reference +4% -4% +2%






[3.4 – 10.5] 0.04
Reference ±0% +7% +5%






[3.4 – 12.4] 0.95
Reference +5% +6% +3%
Absolute values are provided as median and [interquartile range] in pmol/L. Percentages indicate mean change 
compared to reference value. A Exceeding the Acceptable Change Limit (predefined as 25% for vasopressin and 19% 
for copeptin).    S p<0.05 compared to reference value.
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Discussion 
Our study showed that centrifugation speed, short-term storage temperature (pre- as 
well as post-centrifugation), and repeated freezing and thawing had a considerable 
effect on vasopressin levels, but not on copeptin concentrations. Long-term storage for 
4 months at -80°C and -150°C did not affect plasma vasopressin nor copeptin levels, but 
vasopressin concentration decreased significantly when stored at -20°C. 
Our observation that a decrease in plasma platelet count, induced by higher 
centrifugation speed, was accompanied by a decrease in plasma vasopressin 
concentration is in agreement with findings published already 20 years ago.14,22 In one 
of these studies it was demonstrated that platelet-rich plasma (centrifuged at 950 RMP 
for 10 minutes) and platelet-free plasma (additional centrifuging at 15000 RMP for 15 
minutes) differed considerably regarding vasopressin levels and it was concluded that 
~90% of circulating vasopressin was bound to platelets via V1 receptor binding.22,23 To 
our knowledge, our study is the first to show that copeptin concentration, in contrast to 
vasopressin concentration, is not influenced by centrifugation speed, which suggests 
that copeptin is not platelet-bound. The correlations between vasopressin and 
copeptin were significant when centrifuged at 2000 g or 5000 g and differed across the 
various centrifugation speeds, with the strongest correlations being obtained at the 
highest centrifugation speed. We assume that the variation in measured vasopressin 
concentration is greater when a lower centrifugation speed is used due to inter-
individual differences in platelet count, explaining the lower correlation coefficient. 
Differences in centrifugation speed may possibly explain differences in correlations 
between vasopressin and copeptin that have been published in previous studies, 
ranging from 0.31 to 0.88.3,6,24,25 Our results emphasize both the importance of using 
a uniform centrifugation speed and the need of a clear description of the applied 
centrifugation speed in studies that measure vasopressin concentration. Specifically, 
g-force (RCF), as opposed to the rounds per minute (RPM) should be stated, since the 
RCF takes into account the centrifuge diameter.  
In addition to centrifugation force, short-term storage temperature and time before 
processing blood samples affected vasopressin concentration. Vasopressin was found 
to be less stable in whole blood than in plasma. Also, storage temperature of 25°C led 
to less stability of vasopressin in both whole blood and plasma compared to 4°C. We 
observed that  vasopressin concentration in whole blood increased significantly over 
time, both at room temperature (25°C) and 4°C. This may be explained by the fact that in 
plasma after centrifugation free vasopressin is measured, not platelet-bound vasopressin, 
and that vasopressin is released from platelets during storage, leading to an increase in 
measured concentration. Two previous studies also showed an increase in vasopressin 
levels when whole blood was stored at 25°C with greater stability when blood samples 
were stored at 4°C.14,26 However, in these studies vasopressin in whole blood stored at 4°C 
comparison of ex vivo stability of copeptin and vasopressin
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had longer stability than in our study; at least 2426 and even up to 48 hours14 compared 
to 6 hours in the present study. These differences may be explained by the lack of power 
of the statistical tests implemented in these studies, due to an insufficient number of 
participants. The stability of vasopressin in plasma observed in our study is in line with 
literature.22,27 Although we did not specifically study the effect of centrifuge temperature it 
can be expected, based on our results of short-term storage temperature of whole blood, 
that vasopressin levels are more stable in blood centrifuged at 4°C in comparison to 25°C. 
Indeed, a previous study showed that vasopressin levels were lower after centrifugation 
at 4°C in comparison to 25°C (14). In contrast to vasopressin, copeptin was not affected by 
storage temperature conditions. Our results of a stable copeptin concentration for at least 
24 hours in whole blood and plasma is in agreement with previous findings.3,28 
The present study is the first to show that both vasopressin and copeptin are stable in 
plasma when stored frozen at -80°C and -150°C for at least four months. When stored at 
-20°C, plasma vasopressin remained stable for only one month, whereas copeptin was 
stable for at least 4 months. The finding with respect to vasopressin stability established 
at -20°C in our study is in contrast with findings in a previous study that showed that 
vasopressin is not stable when stored for 24 hours.29 This study was, however, performed 
in the seventies and discrepancies might be a caused by differences in the vasopressin 
assay that was used, which has improved significantly over the years,14 or by blood 
collection in lithium heparin instead of EDTA collection tubes.27 
We observed that vasopressin was affected by repeated freezing and thawing, 
whereas no effect on copeptin levels was found up to 4 freeze-thaw cycles. A trend for 
a decrease in vasopressin concentration was observed after already one freeze-thaw 
cycle. Moreover, we found that the extent of the effect of freezing and thawing on the 
vasopressin concentrations varied across samples that were studies, indicating that 
repeated freeze-thaw cycles induce beside a systematic decrease also more variability, 
which both are undesirable. Literature on the effect of freezing and thawing is scarce. 
To our knowledge, only one study reported that vasopressin level did not change after 
three subsequent freeze-thaw cycles.29 However, this has only been studied in one 
sample. Likewise, only one study investigated the effect of freezing and thawing on 
copeptin levels and found no effect of 4 freeze-thaw cycles,3 in agreement with our 
findings. 
We acknowledge that this study has limitations. In our study we only examined stability 
during a frozen storage up to 4 months. Future studies should address the stability of 
vasopressin and copeptin stored for longer periods of time. In addition, vasopressin 
and copeptin levels were measured only once in each specific condition, which may 
have increased the chance of unjustly accepting the analytes to be (un)stable. However, 
performing multiple measurements would have required an unfeasible amount of blood 
samples and volume per individual. By using the ACL to conclude whether changes are 
relevant, we corrected for potential measurement errors, because when values exceed 
part 1, chapter 3
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the ACL this provides 95% certainty that a change in analyte concentration is not due 
to assay variability. The implementation of the ACL as measure for stability, opposed 
to merely statistical analysis, is a significant strength of this study. Another strength is 
that our study is the first to compare the effect of several pre-analytic sample handling 
conditions on vasopressin and copeptin within the same study. In addition, this study 
is an investigator-initiated study and performed independently of the manufactures of 
the copeptin and vasopressin assays.  
Based on our study results pre-analytical sample handling recommendations can be 
made. For measurement of vasopressin, blood samples should be collected on ice and 
centrifuged at 4°C immediately after collection at preferably 2000 g or higher RCF. Short-
term storage of plasma samples is preferred at 4°C for a maximum time span of 24 hours 
or, if storage for a longer period is inevitable, plasma samples should be stored at -80°C. 
Repeated freeze-thaw cycles should be avoided. For measurement of copeptin, a less 
stringent pre-analytical sample handling protocol is necessary as copeptin remained 
stable in all study conditions.
Conclusion 
This study provides more insight in the ex vivo stability of vasopressin and copeptin 
and adds to the knowledge on optimal sample handling in order to perform reliable 
measurements. In view of our results, we recommend the use of a strict sample handling 
protocol in measurements of vasopressin, both to improve between study comparison 
of vasopressin levels as to ensure within-laboratory consistency. In contrast, a less strict 
protocol for copeptin is required, making measurement of copeptin as surrogate for 
vasopressin an attractive alternative.
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In total, nine outliers out of 520 measurements (1.7%) were excluded from the analyses. 
Outliers were defined as values greater than 2.29 standard deviations from the mean 
percentage change of that study condition, detected using Grub’s analysis.19,20 These 
outliers were extremes, most likely explained by measurement errors.
Supplementary Table 1. 
Study condition Number of outliers
Mean percentage 
change with outliers




WB at 25°C for 24h 1 +375%A +247%A
WB at 4°C for 2h 2 +78%A -7%
WB at 4°C for 6h 1 +46%A +20%
Long term storage 
-20°C for 1 month 1 +6% -9%
-150°C for 4 months 2 +30%A -2%
Freeze- thaw cycles
4 cycles 1 -17% -32%A
Copeptin 
Short term storage
Plasma at 4°C for 2h 1 +7% +3%
Legend: WB: whole blood. Percentages indicate mean change compared to reference value. A  Exceeding the 
Acceptable Change Limit (predefined as 25% for vasopressin and 19% for copeptin). 
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Supplementary Figure 1. Effect of repeated freezing and thawing on plasma vasopressin and 
copeptin levels.
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